Drugs Made In America Acquisition II (DMII) Income Statement (2024 - 2026)
Income Statement report data from Sep 30, 2024 to Mar 31, 2026 for Drugs Made In America Acquisition II (DMII).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | |
|---|---|---|---|---|---|---|
Operating Expenses | ||||||
Selling General And Administrative | 130K (-45.83%) | 240K (+50.00%) | 160K (+300.00%) | 40K (-33.33%) | 60K (+50.00%) | 40K |
Operating Expenses | 130K (-87.62%) | 1.05M (+556.25%) | 160K (+300.00%) | 40K (-33.33%) | 60K (+50.00%) | 40K |
Operating Income | ||||||
Operating Income | -130.00K (-87.62%) | -1.05M (+556.25%) | -160.00K (+300.00%) | -40.00K (-33.33%) | -60.00K (+50.00%) | -40.00K |
EBITDA | -130.00K | - | -160.00K (+300.00%) | -40.00K (-33.33%) | -60.00K (+50.00%) | -40.00K |
Other Income / Expenses | ||||||
Interest Income | 4.44M (-7.88%) | 4.82M (+4281.82%) | 110K | - | - | - |
Net Interest Income | 4.44M (-7.88%) | 4.82M (+4281.82%) | 110K | - | - | - |
Net Income | ||||||
Income Before Tax | 4.34M (+0.23%) | 4.33M | -50.00K (+25.00%) | -40.00K (-33.33%) | -60.00K (+50.00%) | -40.00K |
Net Income From Continuing Operations | 4.34M (+0.23%) | 4.33M | -50.00K (+25.00%) | -40.00K (-33.33%) | -60.00K | - |
Net Income | 4.34M (+0.23%) | 4.33M | -50.00K (+25.00%) | -40.00K (-33.33%) | -60.00K (+50.00%) | -40.00K |